Overall, this work delivers the first comprehensive characterization of ARHGEF12’s genetic regulatory role in BLCA risk, prognosis, and chemoresistance, highlighting it as a promising target for precision therapy. Here, ARHGEF12 is linked to bladder transitional cell carcinoma.